Abstract:Integrin alpha(v)beta(3) has been well-documented as one of the key players in the process of tumor angiogenesis. Radiolabeled RGD (Arg-Gly-Asp) peptides (flat specifically target integrin alpha(v)beta(3) have Potential for tumor early detection and noninvasively monitoring the status Of tumor angiogenesis. We developed a cyclic RGD dimeric probe Tc-99m-HYNIC-Gly(3)-E[PGDfK)](2) (Tc-99m-G(3)-2P(4)-RGD2) (using tricine and TPPTS as the coligands, TPPTS = trisodium triphenylphosphine-3,3',3 "-trisulfonate and investigated whether it could be used to noninvasively visualize and quantify integrin alpha(v)beta(3) expression in vivo. HYNIC-Gly(3)-E[PEG(4)-c(RGDfK)](2) was synthesized and labeled with Tc-99m. The biodistribution and planar gamma-imaging studies of Tc-99m-G(3)-2P(4)-RGD2 were performed ill both U87MG (human integrin alpha(v)beta(3) Positive/murine integrin alpha(v)beta(3) positive) and HT-29 (human integrin alpha(v)beta(3) negligible /murine integrin alpha(v)beta(3) positive) tumor-bearing nude mouse models. The correlation of Tc-99m-G(3)-2P(4)-RGD2 tumor uptake values (measured by ex vivo biodistribution) with expression levels Of human integrin alpha(v)beta(3) or murine integrin alpha(v)beta(3) (measured by Western blot) were determined in U87MG and HT-29 tumor models, respectively. Tc-99m-G(3)-2P(4)-RGD2 exhibited increased receptor binding affinity and ill vivo tumor uptake as compared with previously reported RGD dimeric tracer Tc-99m-RGD2 (Without Gly(3) and PEG(4) spacers). The tumor uptake of Tc-99m-G(3)-2P(4)-RGD2 wits related to the expression levels of both human integrin alpha(v)beta(3) (expressed on compared cells) and murine integrin alpha(v)beta(3) (expressed on newborn tumor vasculature). Our results demonstrate that. Tc-99m-G(3)-2P(4)-RGD2 is a useful agent for integrin alpha(v)beta(3) imaging. The relationship between Tc-99m-G(3)-2P(4)-RGD2 uptake and integrin alpha(v)beta(3) expression level its determined by this study would provide useful information for clinical translation of RGD probes.

Present and Future Prospect of Studies of the RGD Peptide Tumor Targeting Receptor Imaging

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Development of Rgd-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

Molecular Basis For The Targeted Binding Of Rgd-Containing Peptide To Integrin Alpha(V)Beta(3)

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging

A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Noninvasive Imaging of Tumor Integrin Expression Using 18 F-labeled RGD Dimer Peptide with PEG 4 Linkers

Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis

Progress on radionuclide-labeled small peptides in targeting tumor angiogenesis

PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin αvβ3 Receptors

Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis

A New Cyclic RGD Peptide Dimer for Integrin Αvβ3 Imaging.

Tumor uptake of the RGD dimeric probe99mTc-G3-2P 4-RGD2 is correlated with integrin αv/β 3 expressed on both tumor cells and neovasculature

Recent Research Progress of RGD Peptide–Modified Nanodrug Delivery Systems in Tumor Therapy